Abstract Library

#745 Surgery after Peptide Receptor Radionuclide Therapy (PRRT) for Patients with Neuroendocrine Tumors (NETs) with Metastatic Abdominal Localizations.

Introduction: There are only few case reports about surgery in patients affected by gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients previously underwent peptide receptor radionuclide therapy (PRRT).

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Bertani E

Authors: Bertani E, Fazio N, Cossu M, Chiappa A, Corbellini C,

Keywords: gastroenteropancreatic neuroendocrine tumors, surgery, peptide receptor radionuclide therapy, multidisciplinary approach, long-term survival.,

#506 Paraneoplastic Neurological Syndrome in a Patient with a Pancreatic Well-Differentiated Endocrine Tumor

Introduction: Few studies report the association of neurological syndromes with a carcinoid, the majority being small-cell lung cancer.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Brizzi M, Ferrero A, Ottone A, Bellini E, Bitossi R,

Keywords: paraneoplastic syndrome,

#431 Everolimus Controlled Resistant Hypoglycemia in Malignant Insulinoma

Introduction: A pancreatic neuroendocrine carcinoma with liver metastases was diagnosed on July 2006 in a 65-year-old man. He was treated with octreotide LAR 30 mg for three years. At liver progression he was enrolled in a multicenter Italian trial titled “XELBEVOCT” with Bevacizumab + Metronomic Capecitabine + Octreotide LAR 30 mg. After seven months, the patient exhibited severe hypoglycemic syndrome with HGT serum levels

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Ferrero A, Bellini E, Brizzi M, Pia A, Ottone A,

Keywords: malignant insulinoma, everolimus, resistant hypoglycemia,